First Trust Nasdaq Pharmaceuticals ETF Rating $27.38 +0.25 (+0.92%) (As of 11/20/2024 ET) Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrends First Trust Nasdaq Pharmaceuticals ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FTXH Aggregate RatingModerate Buy 2.60Holdings in FTXH have an aggregate rating of Moderate Buy based on 727 analyst ratings issued in the past year covering 50 companies (99.8% of the portfolio).FTXH Aggregate Price Target$27.38High Prediction$27.38Average Prediction$27.38Low Prediction$27.38Holdings in FTXH have an aggregate price target of $27.38 and a range of $27.38 to $27.38 covering 50 companies (99.8% of the portfolio).FTXH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy11 Buy rating(s)Moderate Buy30 Moderate Buy rating(s)Hold8 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by First Trust Nasdaq Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 FTXH Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings8.92%BMYBristol-Myers Squibb$58.00+0.2%4.7781 of 5 stars2.20$54.07 -6.8%20Analyst Revision7.32%JNJJohnson & Johnson$153.54+0.3%4.9639 of 5 stars2.53$175.94 14.6%15Positive News6.72%PFEPfizer$24.86-0.3%5 of 5 stars2.50$32.92 32.4%16Analyst DowngradeAnalyst Revision6.64%ABBVAbbVie$167.45-0.2%4.9624 of 5 stars2.90$203.37 21.5%21Analyst ForecastPositive News6.39%MRKMerck & Co., Inc.$97.50+0.1%4.9964 of 5 stars2.68$130.86 34.2%19Dividend IncreasePositive News4.39%GILDGilead Sciences$88.27-0.4%4.549 of 5 stars2.65$94.45 7.0%26Analyst UpgradePositive News4.22%VTRSViatris$13.131.3514 of 5 stars2.00$13.33 1.5%34.17%CAHCardinal Health$120.34+1.7%4.8258 of 5 stars2.46$123.00 2.2%133.77%ZTSZoetis$175.67+0.1%4.8598 of 5 stars3.10$221.44 26.1%10Positive News3.74%UTHRUnited Therapeutics$364.33+1.0%4.5219 of 5 stars2.73$370.86 1.8%15Analyst RevisionPositive News3.37%JAZZJazz Pharmaceuticals$121.40+1.8%4.9183 of 5 stars2.80$175.33 44.4%15Analyst Forecast3.27%AMGNAmgen$285.11-1.0%4.9084 of 5 stars2.46$333.57 17.0%26Ex-DividendShort Interest ↓3.02%BIIBBiogen$154.88-0.4%4.8649 of 5 stars2.54$257.20 66.1%28Analyst Downgrade2.97%LLYEli Lilly and Company$755.20+0.2%4.9913 of 5 stars2.81$1,007.94 33.5%21Analyst Revision2.52%REGNRegeneron Pharmaceuticals$743.35-0.2%4.7877 of 5 stars2.78$1,099.55 47.9%232.48%OGNOrganon & Co.$14.78+0.3%4.7298 of 5 stars2.50$21.33 44.3%42.43%CRLCharles River Laboratories International$187.90+1.0%4.8024 of 5 stars1.93$214.38 14.1%15Analyst Downgrade1.81%ELANElanco Animal Health$13.44+1.0%4.1237 of 5 stars2.43$17.14 27.6%71.71%MEDPMedpace$326.09+3.5%4.7711 of 5 stars2.45$380.00 16.5%111.37%NBIXNeurocrine Biosciences$122.60-0.6%4.9503 of 5 stars2.83$163.91 33.7%24Positive News1.14%EXELExelixis$34.72+0.2%4.7763 of 5 stars2.65$31.44 -9.4%20Insider Trade1.07%ALKSAlkermes$28.01+0.4%4.7847 of 5 stars2.58$35.42 26.4%12Positive News1.00%PRGOPerrigo$27.15-0.3%4.9798 of 5 stars2.75$37.00 36.3%4Positive News0.99%PBHPrestige Consumer Healthcare$82.67+0.3%3.6888 of 5 stars2.67$83.67 1.2%30.97%HALOHalozyme Therapeutics$45.69-0.2%4.9812 of 5 stars2.60$61.11 33.8%10Analyst Forecast0.81%CORTCorcept Therapeutics$55.00-1.9%4.6673 of 5 stars3.00$65.25 18.6%50.72%PTGXProtagonist Therapeutics$40.65+5.2%3.0296 of 5 stars3.14$53.57 31.8%7Analyst ForecastAnalyst RevisionNews Coverage0.70%ACLXArcellx$87.22-0.4%2.9324 of 5 stars3.07$103.08 18.2%14Short Interest ↓0.69%TGTXTG Therapeutics$31.83+2.2%4.2178 of 5 stars2.83$37.67 18.3%6Positive News0.64%INCYIncyte$71.05+0.7%3.912 of 5 stars2.38$77.16 8.6%21Analyst Forecast0.61%ADMAADMA Biologics$21.45+0.4%3.3177 of 5 stars3.25$21.25 -0.9%40.61%ITCIIntra-Cellular Therapies$85.96+0.4%4.4721 of 5 stars2.85$97.23 13.1%13Positive News0.60%ALNYAlnylam Pharmaceuticals$247.58-0.5%4.3981 of 5 stars2.71$298.09 20.4%24Analyst Forecast0.56%ACADACADIA Pharmaceuticals$15.76-2.8%3.9104 of 5 stars2.65$25.56 62.2%17Insider TradeAnalyst Revision0.56%VCELVericel$57.26+2.6%1.0997 of 5 stars3.00$58.14 1.5%7Analyst Forecast0.52%TWSTTwist Bioscience$40.69-1.0%4.1398 of 5 stars2.67$51.78 27.2%9Analyst ForecastAnalyst RevisionNews Coverage0.52%AMRXAmneal Pharmaceuticals$8.38-0.4%3.211 of 5 stars2.80$10.00 19.3%5Insider Trade0.51%BPMCBlueprint Medicines$94.81+0.2%2.713 of 5 stars2.71$122.11 28.8%21Analyst ForecastAnalyst Revision0.51%RNAAvidity Biosciences$43.06-1.4%2.4064 of 5 stars3.00$63.22 46.8%9Insider TradeAnalyst Revision0.51%VRTXVertex Pharmaceuticals$445.25-1.3%4.0527 of 5 stars2.53$499.12 12.1%30Analyst DowngradeNews CoveragePositive News0.50%ROIVRoivant Sciences$11.62+1.1%3.2845 of 5 stars2.88$17.93 54.3%80.49%KRYSKrystal Biotech$177.89-0.1%4.7558 of 5 stars3.00$202.29 13.7%8Positive News0.48%KYMRKymera Therapeutics$43.83-0.5%1.4071 of 5 stars2.81$52.13 18.9%16Analyst Forecast0.47%INSMInsmed$71.86-1.1%4.0562 of 5 stars3.00$83.07 15.6%160.44%EXASExact Sciences$52.29-0.8%4.8868 of 5 stars2.95$74.47 42.4%19Positive News0.42%BMRNBioMarin Pharmaceutical$62.56+1.0%4.9885 of 5 stars2.74$94.20 50.6%23Analyst Revision0.42%SRPTSarepta Therapeutics$109.71-1.0%4.914 of 5 stars3.00$181.33 65.3%22Analyst DowngradeGap Up0.42%VKTXViking Therapeutics$50.76-1.5%4.7696 of 5 stars3.09$109.80 116.3%11Analyst ForecastGap Up0.39%IONSIonis Pharmaceuticals$35.40+4.9%4.2328 of 5 stars2.68$60.65 71.3%190.29%MYGNMyriad Genetics$15.30+2.0%4.2579 of 5 stars2.42$27.36 78.8%12Analyst Forecast This page (NASDAQ:FTXH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust Nasdaq Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust Nasdaq Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.